Modeling preventative strategies against human papillomavirus-related disease in developed countries

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Canfell, Karen ^a,b   Chesson, Harrell ^c   Kulasingam, Shalini L ^d   Berkhof, Johannes ^e   Diaz, Mireia ^f   Kim, Jane J ^g  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anal; Anogenital warts; Cervical cancer screening; Cost effectiveness analysis; Developed countries; Hpv; Intraepithelial neoplasia; Mathematical models; Oral cavity and oropharyngeal cancer; Recurrent respiratory papillomatosis; Uterine cervical neoplasms; Vaccines; Vaginal; Vulvar

Indexed keywords

WART VIRUS VACCINE;

CANCER SCREENING; CLINICAL EVALUATION; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DECISION MAKING; DEVELOPED COUNTRY; DRUG COST; HUMAN; IMMUNOPROPHYLAXIS; MALE HOMOSEXUAL; MATHEMATICAL MODEL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCREENING TEST; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

EID: 84877030450     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.091     Document Type: Review

References (90)

1. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012 Jun;13(6):607-15.
2. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007 6/25/2007;111(3):145-53.
3. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008;26(SUPPL 10):K76-86.
4. Brisson M, van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009;12(5-6):343-51.
5. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364(5):401-11.
6. Palefsky JM, Giuliano AR, Goldstone S, Moreira Jr ED, Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011 Oct 27;365(17):1576-85.
7. Centers for Disease Control and Prevention. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011 Dec 23;60:1705-8.
8. PBAC. Pharmaceutical Benefits Advisory Committee (Australia): November 2011 PBAC Outcomes - Positive Recommendations. Canberra, Australia2011. Available at: http://www.pbs.gov.au/info/industry/listing/elements/pbacmeetings/pbac-outcomes/2011-11/positive-recommendations (last accessed May 2012).
9. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010 Nov;11(11):1048-56.
10. Peres J. For cancers caused by HPV, two vaccines were just the beginning. J Natl Cancer Inst 2011;103(5):360-2.
11. Berkhof J, Bogaards JA, Demirel E, Diaz M, Sharma M, Kim J.J. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Vaccine, in press.
12. Hillemanns P, Petry K, Largeron N, McAllister R, Tolley K, Büsch K. Costeffectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health (Oxf) 2009;17(2):77-86.
13. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008;14(2):244-51.
14. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011;343:d5775.
15. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359(8):821-32.
16. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Medicine 2006;3(5):e138.
17. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006;24(SUPPL 3). S3/178-S3/86.
18. Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007 Apr 1;165(7):762-75.
19. Rogoza RM, Ferko N, Bentley J, Meijer CJ, Berkhof J, Wang KL, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 2008;26(SUPPL 5):F46-58.
20. Mennini FS, Giorgi RP, Palazzo F, Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009;112(2):370-6.
21. La Torre G, de Waure C, Chiaradia G, Mannocci A, Capri S, Ricciardi W. The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy. Vaccine 2010;28(19):3379-84.
22. Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Vaccine 2008;26(44):5654-61.
23. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme. Eur J Public Health 2010 Apr;20(2):213-9.
24. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008 Jul;115(8):947-56.
25. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc 2008;6:4.
26. Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, et al. Comparison of detailed and succinct cohort modelling approaches in a multiregional evaluation of cervical cancer vaccination. Vaccine 2008;26(SUPPL 5):F16-28.
27. Coupe VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based costeffectiveness. Int J Cancer 2009;124(4):970-8.
28. Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009;27(35): 4776-83.
29. Boot HJ, Wallenburg I, de Melker HE, Mangen MJ, Gerritsen AA, van der Maas NA, et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 2007 Aug 14;25(33):6245-56.
30. de Kok IM, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009;101(15):1083-92.
31. Coupe VM, Meijer CJ, Berkhof J. Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2010;102(5):358.
32. de Kok IM, van Ballegooijen M, Habbema JDF. Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands: Response to Coupe. J Natl Cancer Inst 2010;102(5):358.
33. Rozenbaum MH, Boersma C. Response: Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2010;102(5):358-9.
34. de Kok IM, van Ballegooijen M, Habbema JDF. Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands: Response to Rozenbaum. J Natl Cancer Inst 2010;102(5):359.
35. de Kok IM, Habbema JD, van Rosmalen J, van Ballegooijen M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer 2011 Feb;47(3):428-35.
36. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008;24(1.).
37. Thiry N, De Laet C, Hulstaert F, Neyt M, Huybrechts M, Cleemput I. Costeffectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009 Apr;25(2):161-70.
38. Szucs TD, Largeron N, Dedes KJ, Rafia R, Benard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008;24(5).
39. Demarteau N, Detournay B, Tehard B, El Hasnaoui A, Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health 2011 Apr;56(2):153-62.
40. Dasbach EJ, Largeron N, Elbasha EH. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoecon Outcomes Res 2008 Oct;8(5):491-500.
41. Dasbach EJ, Nagy L, Brandtmuller A, Elbasha EH. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ 2010 Mar;13(1):110-8.
42. Elbasha EH, Dasbach EJ, Insinga RP, Haupt RM, Barr E. Age-based programs for vaccination against HPV. Value Health 2009 Jul-Aug;12(5):697-707.
43. Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ, et al. Until which age should women Be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses J Infect Dis 2011;204(3):377-84.
44. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008;337:a769.
45. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010 Apr;26(2):183-91.
46. Bogaards JA, Coupe VM, Meijer CJ, Berkhof J. The clinical benefit and costeffectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine 2011 Nov 8;29(48):8929-36.
47. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009;151(8):538-45.
48. Baussano I, Garnett G, Segnan N, Ronco G, Vineis P. Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine 2011;29(6):1270-7.
49. Brisson M, van de Velde N, VFranco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011; 204(3):372-6.
50. Bogaards JA, Kretzschmar M, Xiridou M, Meijer CJ, Berkhof J, Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med 2011 Dec;8(12):e1001147.
51. French KM, Barnabas RV, Lehtinen M, Kontula O, Pukkala E, Dillner J, et al. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007;96(3):514-8.
52. Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 2011;29(48):9112-22.
53. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884.
54. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28(42):6858-67.
55. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011;29(46):8443-50.
56. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10(11):1915-23.
57. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 2009 Aug 13;27(37):5133-41.
58. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years-United States, 2010. MMWR Morb Mortal Wkly Rep 2011 Aug 26;60(33):1117-23.
59. Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health 2011 Jun;8(2):171-8.
60. Castle PE, Scarinci I. Should HPV vaccine be given to men? BMJ 2009;339:b4127.
61. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101(2):270-80.
62. D'Souza G, Wiley DJ, Li X, Chmiel JS, Margolick JB, Cranston RD, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008;48(4):491-9.
63. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010;10(12):845-52.
64. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103(19): 1444-51.
65. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J Infect Dis 2011 Aug 1;204(3):372-6.
66. Castle PE, Zhao FH. Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs. J Infect Dis 2011;204(3):335-7.
67. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011 Nov 10;29(32):4294-301.
68. Brisson M, van de Velde N, Boily MC. Impact of disparities in HPV vaccine coverage on population-level effectiveness. In: 26th International papillomavirus conference. 2010.
69. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential costeffectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25(29):5399-408.
70. Lee VJ, Tay SK, Teoh YL, Tok MY. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health 2011;11:203.
71. Kmietowicz Z. UK will use Gardasil in its HPV vaccination programme from next September. BMJ 2011;343:d7694.
72. Bonanni P, Boccalini S, Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence. Vaccine 2009;27(SUPPL 1):A46-53.
73. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5(10):705-19.
74. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;2:926-35.
75. Paavonen J, Naud P, Salmeron J, Wheeler C, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374(9686):301-14.
76. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008 Aug 19;26(SUPPL 10):K53-61.
77. Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 2010;13(2):324-38.
78. Capri S, Gasparini R, Panatto D, Demarteau N. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles. Gynecol Oncol 2011 Jun 1;121(3):514-21.
79. Van de Velde N, Malagon T, Drolet M, Laprise J, Boily M, Brisson M. Modeling the effectiveness of the bivalent, quadrivalent and nonavalent vaccines. In: 27th International Papillomavirus Conference and Clinical Workshop; September 17-22. 2011.
80. Cuzick J, Castañón A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010;102(5):933-9.
81. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377(9783):2085-92.
82. Kulasingam SL, Pagliusi S, Myers E. Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S. Vaccine 2007;25(48):8110-3.
83. Berkhof J, Coupe VM, Bogaards JA, van Kemenade FJ, Helmerhorst TJ, Snijders PJ, et al. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 2010;127(9):2147-58.
84. Coupe VM, Bogaards JA, Meijer CJ, Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening 2012;30(10):1813-22.
85. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ. Costeffectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 2008;100(5):308-20.
86. Diaz M, de Sanjose S, Ortendahl J, O'Shea M, Goldie SJ, Bosch FX, et al. Costeffectiveness of human papillomavirus vaccination and screening in Spain. Eur J Cancer 2010;46(16):2973-85.
87. Creighton P, Lew JB, Clements M, Smith M, Howard K, Dyer S, et al. Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health 2010;10:734.
88. Moyer VA. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012;156(12):880-91.
89. Health Protection Agency Immunisation Section: Annual HPV vaccine coverage in England in 2010/2011: Routine programme for school year 8 females (12 to 13 years old). Available at: http://immunisation.dh.gov.uk/annual-hpvvaccine-coverage-in-england-in-201011-report/(last accessed March 2012).
90. National Health and Medical Research Council (Australia): Screening to Prevent Cervical Cancer: Guidelines for the Management of Asymptomatic Women with Screen Detected Abnormalities. Canberra, 2005.